BIAL Established as new Marketing Partner for Medigene's Drug Veregen® in Spain and Portugal
(Thomson Reuters ONE) -
MediGene AG /
BIAL Established as new Marketing Partner for Medigene's Drug Veregen® in Spain
and Portugal
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Market launch in Spain still scheduled for the 2nd quarter of 2012
Martinsried/Munich, May 4, 2012. MediGene AG (MDG, Frankfurt, Prime Standard)
announces that its drug Veregen(®) will now be marketed by BIAL Industrial
Farmaceutica, S.A., with immediate effect. This announcement follows an
agreement between Medigene, its previous partner Juste S.A.Q.F and the
Portuguese pharmaceutical company BIAL. Market launch of Veregen(®) ointment in
Spain remains scheduled to take place in the second quarter of 2012.
Dr. Frank Mathias, Chief Executive Officer of Medigene, comments: "This is a
benefit for Veregen(®), as our new partner BIAL has an extremely powerful
marketing organization. We look forward to working with this highly competent
partner who plays a leading role on the Iberian Peninsula."
Commenting about Veregen(®) launch António Portela, CEO of BIAL, said:
"Veregen(®) is an important addition to our current gyneacology portfolio. We
are very excited to strengthen our portfolio with such an innovative and unique
product. Our team has high expectations for the launch of Veregen(®)."
Veregen(®) is currently available on the US, German, and Austrian markets.
Market launch in Spain is in preparation. In Switzerland, the reimbursable price
is currently being negotiated. In addition, marketing authorization applications
for an additional 17 European countries were assessed positively by the
regulatory authorities in March 2012. Medigene expects that the national
marketing authorizations will be formally granted by the respective regulatory
authorities within the next few months.
Medigene has entered into several marketing partnerships for Veregen(®),
including Fougera (formerly Nycomed) for the United States; Abbott for Germany,
Austria, and Switzerland; Laboratoires Expanscience for France; and a number of
other partners across Europe, America, and Asia. Medigene is planning to
continue this global licensing strategy.
About Veregen(®): Veregen(®) (previously Polyphenon E(®) ointment), a topical
treatment for external genital warts, contains a concentrate of catechins with a
complex defined composition extracted from green tea leaves. Medigene acquired
the basic rights to the active ingredient in Veregen(®) from Epitome
Pharmaceuticals, Inc. in 1999, and was solely responsible for the drug's
successful preclinical and clinical development, as well as the approval
process. Sinecatechins 15% ointment (Veregen(®)) is recommended as a possible
option for treating genital warts in the US Department of Health and Human
Services Center for Disease Control
About BIAL: BIAL, founded in 1924, is a global pharmaceutical company with
products marketed in 50 countries on 4 continents. The privately owned company
ranks number 5 on the Portuguese pharmaceutical market and has a strong presence
on the Iberian Peninsula, in Latin America as well as in French and Portuguese
speaking countries in Africa. BIAL is strongly committed to therapeutic
innovation investing more than 20% of its turnover in research and development
every year. Key research areas for BIAL are the central nervous system, the
cardiovascular system and allergen immunotherapy. BIAL currently has several
other innovative programs under development, which the company expects to bring
to the market within the next years, thereby strengthening its position
throughout Europe. For further details, please visit www.bial.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of MediGene AG. These
trademarks may be owned or licensed in select locations only.
- End -
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials and is developing an innovative vaccine
technology.
Contact
Julia Hofmann & Kerstin Langlotz
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
press release as pdf:
http://hugin.info/132073/R/1608684/510645.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
[HUG#1608684]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.05.2012 - 02:30 Uhr
Sprache: Deutsch
News-ID 1110691
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 103 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BIAL Established as new Marketing Partner for Medigene's Drug Veregen® in Spain and Portugal
"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).